Patients with a very high level had more comorbidities, notably PAD (12.2% vs 7.7% or 6.2%; P < .001) and ischemic heart disease (19.2% vs 16.7% or 13.3%; P < .001) compared with those with high or normal Lp(a) levels. The gene discussed is LPA; the disease is peripheral arterial disease.